Catalent, Inc. to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that members of its executive leadership team will participate at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, at 5:15 p.m. ET.
A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.
About Catalent
Catalent, Inc., is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent's expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.
The World Federation of Neurology (WFN) is pleased to announce Brain Health and Prevention as the theme for the 2024 World Brain Day (WBD 2024), taking place on Monday, July 22. The goal is to raise critical awareness to prevent brain disease in all...
Regulatory News:
Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...
Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative drugs for the treatment of rare genetic diseases, utilizing its proprietary CRISPR-based epigenome editing technology CRISPR-GNDM®, posted the...
Exams can be daunting for students and parents, but with the right approach it can become a rewarding and manageable experience. Expert private tutors can support academic study and exam-readiness while promoting students' mental health with...
As part of its Global Science Summit, the Novo Nordisk Foundation issues an international open call for research projects to catalyse science-based solutions to key global challenges. The programme expects to hand out up to eight grants with a total...
"Nando", a leading Lithuanian-owned biotechnology company known for its groundbreaking work in developing microbiological products for agriculture, that helped to save up to 50M on fertilisers, announces a significant bolstering of its...
